Wellington Management Group
TRVI icon

Wellington Management Group’s Trevi Therapeutics TRVI Stock Holding History

Wellington Management Group’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61.9M Buy
5,189,088
+1,785,098
+52% +$20M 0.01% 667
2025
Q4 		$42.6M Buy
3,403,990
+150,102
+5% +$1.73M 0.01% 777
2025
Q3 		$29.8M Buy
3,253,888
+3,081,906
+1,792% +$23.1M 0.01% 882
2025
Q2 		$941K Buy
171,982
+44,530
+35% +$277K ﹤0.01% 1733
2025
Q1 		$802K Buy
+127,452
New +$608K ﹤0.01% 1752

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Wellington Management Group's TRVI Position: Q1 2026 in Review

Wellington Management Group increased its Trevi Therapeutics (TRVI) stake by 52% in Q1 2026, buying an estimated $20M and bringing the position to 5,189,088 shares worth $61.9M. The position accounts for 0.01% of the portfolio, ranked #667.

Wellington Management Group first reported a position in TRVI in Q1 2025 and has held it in 5 quarters since. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • Wellington Management Group held 5,189,088 shares of Trevi Therapeutics worth $61.9M as of Q1 2026.
  • Wellington Management Group bought 1,785,098 Trevi Therapeutics shares in Q1 2026, an estimated $20M.
  • Trevi Therapeutics made up 0.01% of Wellington Management Group's portfolio in Q1 2026, its #667 holding.
  • Wellington Management Group first reported a position in Trevi Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Wellington Management Group's 13F filing for Q1 2026, filed 15 May 2026.